University of Montana

ScholarWorks at University of Montana
Graduate Student Theses, Dissertations, &
Professional Papers

Graduate School

1988

Ribi ImmunoChem Research Incorporated : a corporate strategy
case study
Jon Stannard
The University of Montana

Follow this and additional works at: https://scholarworks.umt.edu/etd

Let us know how access to this document benefits you.
Recommended Citation
Stannard, Jon, "Ribi ImmunoChem Research Incorporated : a corporate strategy case study" (1988).
Graduate Student Theses, Dissertations, & Professional Papers. 7209.
https://scholarworks.umt.edu/etd/7209

This Thesis is brought to you for free and open access by the Graduate School at ScholarWorks at University of
Montana. It has been accepted for inclusion in Graduate Student Theses, Dissertations, & Professional Papers by an
authorized administrator of ScholarWorks at University of Montana. For more information, please contact
scholarworks@mso.umt.edu.

COPYRIGHT ACT OF 1976
Th i s
SUBSISTS.

is

an

Any

unpublished
further

manuscript

reprinting

of

in

its

which

copyright

contents

must

APPROVED BY THE AUTHOR.
Ma n s f i e l d

Library

Un i v e r s i t y
Date :____

of

Mo n t a n a

1988__

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

be

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

RIBI IMmTWnrRRM RESEARCH. INCORPORATED: A CORPORATE STRATEGY CASE STUDY

Prepared By: Jon Stannard, Graduate Student
School Of Business Administration
University Of Montana
Missoula, Montana

Presented in partial fulfillment of the Master's of Business
Administration Degree requirements.

June 14, 1988
Approval:

I

C ---------

Dr. Paul Larson, Committee Chair

r. Raymond Murray, Graduataf Dean

Date

/

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Date

UMI Number; EP38010

All rights reserved
INFORMATION TO ALL USERS
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.

UMT
OiwMrt«tioft AiUiahins

UMI EP38010
Published by ProQuest LLC (2013). Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against
unauthorized copying under Title 17, United States Code

ProQ^st*
ProQuest LLC.
789 East Eisenhower Parkway
P.O. Box 1346
Ann Arbor, Ml 48106 - 1346

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

ii

ACKNOWLEDGMENTS

I am deeply Indebted to many people who committed time, effort and
support to this project.
Without Nils Ribi's unselfish direction, the project would never
have been more than a passing idea.

Besides managing a company

dedicated to improving health care, Mr
education support.

Rlbl also lends unwavering

Whether through classroom speech engagements,

student interviews, or philanthropic support, he extends tremendous
effort to improve the University of Montana students' education.
Too often students perceive faculty as too busy ornot interested
involunteering assistance to students.

It has

been my

pleasure to work

under the responsible direction of the following capable. Interested,
and supporting faculty: Dr. Paul Larson. Dr. David Weber, Dr. Ralph
Judd, and Dr. Larry Gianchetta.
Writing a professional paper for the first time Is
most people.

Had it not been for the continual support,

not easy for
advice, and

encouragement Dr. Douglas Seed offered, this project would have never
reached completion.
I owe my wife Donna, and children more than I can ever repay.

For

the past six years, they compromised a better life to support my
commitment to work and study.
Finally, In loving memory of my mother, I dedicate this work.
was not her losing bout with cancer that Inspired me to write this
paper; it was my way of making her proud.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

It

iii

TABLE OF CONTENTS

ACKNOWLEDGMENTS........................................ 11
TABLE OF CONTENTS.....................................ill
LIST OF FIGURES........................................vl
LIST OF TABLES.........................................vi

CHAPTER 1: INTRODUCTION................................. 1

CHAPTER 2: COMPANY BACKGROUND.......................... 3
A

Dr. Rlbl. Scientistand Founder..................3

B.

Incorporation................................... 3
Regulation..............

C.

4

Adjuvants....................................... 5

CHAPTER 3: CURRENT COMPANY OPERATIONS.................. 7
A.

The Mission..................................... 7

B.

Marketing/Distribution Strategy.............. ...7

C.

The Products.................................... 8
DETOX*....................................9
OVAMID*..................................11
MPL*..................................... 11
RIBIGEN*................................. 12
Research Products........................ 13

D.

Federal Regulation............................. 14

Reproduced with permission of the copyright owner. Further reproduction prohibited w ithout permission.

iv

E.

Patents and Protection........................ .

F. Staffing........................................16
G.

Facilities.................................... .

H. Financial Condition............................ 20
The Income Statements....................21
The Balance Sheets.......................21
Shareholders' Equity.....................23

CHAPTER 4: THE MARKETS................................. 28
A. Infectious Diseases...........................

29

Vaccines.................................29
Non-Specific Resistance and Immune
System Compromised Patients............. 31
B. Human Cancer Applications...................... 32

detox* ................................. 32
OVAMID*..................................33
Strategic Available Markets............. 33
C.

Animal Cancer Applications..................... 34

D.

Research Products............

35

CHAPTER 5: INDUSTRY’S MAJOR COMPETITORS................ 36
A.

Competition.................................... 36

B.

Industry Segments.............................. 38

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

c.

Limitations to Industry Growth................. 4 j
Innovation Constraints.................. .
Liability Issues........................ .
Cost and Profitability.................. 46

D. Industry Trends................................ 47

CHAPTER 6 : CORPORATE STRATEGY ANALYSIS................. 49
A.

What is the Business Doing Now?................ 49
Assumptions............................. 49
Mission and Strategies.................. 49

B.

What is Happening In the Environment?.......... 52
Industry Analysis....................... 52
Competitor Analysis..................... 53
Societal Analysis....................... 57
Strengths............................... 57
Weaknesses.............................. 60

C. What Should the Business be Doing?............. 61

APPENDIX...............................................64

BIBLIOGRAPHY........................................... 72

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Vi

LIST OP FIGURES

FIGURE 1: Organizational Structure.....................18

FIGURE 2: Major Revenues.............................. 24

FIGURE 3: 1985 Human Vaccine Market Shares............ 45

LIST OP TABLES

TABLE 1: Financial Ratios.............

25

TABLE 2: Detailed Revenue Breakdown................... 25

TABLE 3: Shareholder Data............................. 26

TABLE 4; Pro Forma Cash Flow.......................... 27

TABLE 5:

Biotechnology Products, Competitors.

and Market Share Assumptions...........................39

TABLE 6 : Pro Forma Cash Flow(Revised)................. 63

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

CHAPTER I:
INTRODUCTION

Rlbl ImmunoChem Research, Inc. competes in the highly competitive
biopharmaceutical segment of the biotechnology industry.

Devoted to

improving human health, the Company is racing to develop new-generatlon
health care products that could improve existing malignant and
infectious disease therapy.

Beyond improving existing therapy, the

Company is also researching methods of using its proprietary technology
to prevent certain malignant and infectious disease ailments.
Ribi ImmunoChem Research, Inc.

"is engaged in the research,

development, production, and marketing of biopharmaceutical agents which
can be used as adjuvants"!

Known to boost immune system response to

infection, the Company's adjuvants are gaining considerable recognition.
By researching adjuvant products that are more effective, less toxic,
and void of serious side effects, the Company has earned a reputation as
a world leader in molecular immunotherapy research.
Ribi ImmunoChem Research, Inc. pursues corporate strategy aimed at
perfecting its technology, and moving new-generatlon health care
products to market as quickly as possible.

Managed by a team of

competent business executives who direct the research and production
efforts of skilled research scientists, the Company hopes to soon market
its first adjuvant product intended for human use.

^ Ribi ImmunoChem Research. Inc., SEC Form 10-K (Annual Report).
31 December 1986, p.l.
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This paper will analyze the Company's corporate strategy.
Presented in a case format, the initial chapters will first describe
Ribi ImmunoChem Research,
operations.

Inc.'s historical and current company

Following chapters will examine its markets, and the

industry’s major competitors.

The final chapter will analyze Ribi

ImmunoChem*s strategy in light of Company capability, competition, and
industry trends.

Recommendations will also be included, suggesting

methods of strengthening strategy.
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CHAPTER II:
RIBI IMMUNOCHEM RESEARCH, INC.; COMPANY BACKGROUND

A.

D p . Rlbl, Scientist and Pounder.

After serving thirty years with

the National Institute for Allergy and Disease Control,
Edgar Ribi retired.

in 1981 Dr.

Anxious to continue adjuvant research, he forged

ahead to found the company that bears his name.
Besides founding Ribi ImmunoChem Research,

Inc., Dr. Ribi can be

credited for numerous microbiology research advances.

In the early

1960*s, he invented the Ribi Cell Fractionator, a tool with numerous
invaluable research and production functions.

In 1981, he and his

colleagues discovered a reproducible method for detoxifying endotoxin
while preserving the compound's potent adjuvant properties.

The

adjuvants extracted from endotoxin became the key stimulating
Ingredients for the Company's anti-tumor products.

Finally, until his

unfortunate death in 1986, Dr. Ribi asserted the importance of adjuvants
in future health care through publication of 185 reports, and countless
presentations at national and international science conferences.
adjuvant experts considered Dr

Many

Rlbl the world's leader in adjuvant

research.

B.

IncoPiK>ratlon.

January 9, 1981.

Ribi ImmunoChem Research,

Inc. was incorporated on

Dr. Ribi filed the Company's Articles of Incorporation

in Delaware and located the business in Hamilton, Montana.

Selecting to

file articles of incorporation in Delaware is common among U.S.
corporations because "Delaware imposes the lowest annual franchise tax
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nationally, treats corporations liberally, and Is strategically located
on the East

Coast.

Ribi ImmunoChem Research,

Inc. is a public corporation capitalized

exclusively through issuance of common stock.

Because Ribi and other

public corporations involve the use and custody of stockholder funds and
securities, they are subject to federal and state regulation.

1.

Incorporation— Regulation.

The Securities Exchange Acts of 1933 and

1934, established the Securities and Exchange Commission to regulate
securities markets and trading.
responsibility,

In accordance with their regulatory

the SEC requires Ribi ImmunoChem officers file quarterly

and annual performance reports describing the Company's operating and
financial condition.
State corporate regulation laws vary from state to state, but
generally speaking, they all define the powers granted corporations
Additionally through Blue Sky Law provisions, regulation protects
prospective stockholders from misleading information intended to attract
investment through promises of the "blue sky."
Usually state governments assume regulatory responsibility by
enforcing "state corporation codes."

Although Ribi ImmunoChem

Research, Inc. is a Montana-based foreign corporation (they were
incorporated out-of-state), they are subject to the same Montana codes
as domestic corporations.

Similar to the SEC, Montana law requires Ribi

ImmunoChem file annual performance reports of their financial and

2 Marvin Kristein. Corporation Finance. (New York: Barnes and Noble
Books: 1975), pp. 12-13.
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operating condition.

C.

Adjuvants.

From research pioneered by Dr. William Coley at the turn

of the 2 0 th century, a relationship was discovered between bacterial
Infection and malignant tumor regression.
cancer patient could be injected
immune response.

Often he

Dr. Coley believed that a

with certain bacterium to stimulate an

found the response powerful enough to not

only kill the bacterium intruder, but also the patient's malignant tumor
cells.

Unfortunately, too

practice inappropriate for

often the bacterium was toxic, ruling the
human health care.

Determined that "Dr. Coley's toxins"

could be made safe without

destroying their therapeutical properties. Dr. Ribi spent most of thirty
years researching methods to eliminate the toxicity of endotoxin, one of
Coley's toxins.

In the early 1960's he advanced his research methods

with the invention of the Ribi Cell Fractionator,

"a machine that breaks

bacterial cells apart, allowing the protoplasm (which contains many
contaminants) to be removed from the cell wall, from which a variety of
adjuvants can then be extracted."3
Adjuvants are bacterial-borne chemicals, capable of stimulating a
general immune system response.

They can be applied alone or in

combination with substances (antigens) specifically targeted for
particular ailments.

They have long been perceived by Dr. Ribi and his

Company associates as safe and effective ways for treating and
preventing malignant and infectious disease.

3 "Ribi ImmunoChem Research,
Investors. January. 1988. p.2.

Inc.," Research;

Ideas for Today's
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Rlbl ImmunoChem Research.

Inc.’s products are formulated using four

primary adjuvants: TDM (trehalose dimycolate), CWS (cell wall skeleton).
M P L ^ (monophosphoryl lipid A), and PA-PE (propionibacterium acnespyridine extract).

Mixed together in varying combinations, the

adjuvants have yielded three principle products (DETOX*, OVAMID*, and
RIBIGEN®).

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

CHAPTER III:
RIBI IMMUNOCHEM RESEARCH, INC.; CURRENT COMPANY OPERATIONS

A

The Mission.

Ribi ImmunoChem Research.

Inc. is "engaged in the

research, development, production and marketing of biopharmaceutical
products, which can be used as adjuvants."*
According to Nils Ribi, the Company's Chairman of the Board, "our
corporate mission is to become a fully-integrated pharmaceutical
company, with primary focus on the development and application of
adjuvants for human health care."5

B.

Marketing/Distribution Strategy.

ImmunoChem Research,

Since incorporation, Ribi

Inc. fostered a corporate marketing strategy to

"avoid licensing away its proprietary products and technology in return
for some credibility and minor royalties,"®

The strategy proved

valuable— the Company controls all of its products and technology amidst
considerable industry interest in Ribi ImmunoChem products and
processes.
In seven years of operation, the Company has identified numerous
new adjuvant applications.

Responding to the growth,

in July 1987,

Company officials launched a refined corporate marketing strategy.

They

examined the relationship between two market entry barriers (the

* Rlbl ImmunoChem Research,
31 December 1966, p.l.

Inc., SEC Form 10-K. Annual Report,

® Personal interview with Nils Ribi, Chairman of the Board, Ribi
ImmunoChem Research, Inc., Hamilton, NT, 13 November 1987.
® Ribi ImmunoChem Research,

Inc., 1987 Annual Report, p.2.
7
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research and development time and expense, and Ribi's access to
particular markets), and devised strategy that would generate maximum
product returns.
To date, Rlbl ImmunoChem Research.

Inc. follows the following three

marketing strategies outlined In the Company's 1987 Annual Report;
— > In areas where Rlbl ImmunoChem has already established
leadership (such as DETOX^ and OVAMID^), product development should be
short.

Accordingly,

the Company plans to develop and market the product

itself when the physician target audience is small and market size
substantial.

This should allow the Company to minimize marketing

expense and maximize potential profits.
— > Where the Company's products dovetail with another major
company's research program, Rlbl ImmunoChem plans to seek partnerships
to develop the products.
marketing responsibility.

Once completed, the partner would assume the
This arrangement should provide license fees,

research funding, and royalties as the revenue sources.
— > When a major health care company dominates a particular market
area and Ribi ImmunoChem's adjuvants enhance the other company's
products (as in the area of vaccines). Ribi ImmunoChem intends to
directly license products with accompanying license fees and royalties
as revenue s o u r c e s ?

C.

The Products.

Ribi Immunochem scientists research adjuvant

applications "designed to stimulate an Immune response in man and

Ibid, p.10.
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animals in order to prevent and treat malignant and infectious
disease ." 6

The applications are being developed;

— > to provide human cancer therapy,
— > to boost the activities of vaccines to prevent and treat human
infectious conditions,
— > and to prevent and treat human infectious conditions through
general immune system stimulation.

In February, 1987, Nils Ribi was optimistic that his adjuvants
could include a fourth application--prevention of cancer.

He was

quoted, "right now the approach we're all taking is treating cancer.
Here with this vaccine (using Ribi ImmunoChem adjuvants) lies the
possibility that you can truly have a preventative against cancer.”®
Additionally, to a lesser extent. Ribi ImmunoChem is developing
adjuvants for veterinary uses in preventing and treating both malignant
and Infectious diseases.

1.

The Products— DBTOX*.

One year after incorporation, Ribi

scientists had developed DETOX™, the Company's first adjuvant anti
tumor human health care product.

DETOX™ can be delivered alone to

stimulate a localized Immune response or in combination with a "cancer
vaccine."

Depending on the method of delivery, the product is ideally

suited for therapeutical use in combatting malignant melanoma, Kaposi's

® Ribi Immunochem Research, Inc.. SEC Form 10-K (Annual Report> .
31 December 1986, p.l.
® Greg Lakes, "Keeping Cancer at Bay," Missoulian. 11 February
1987, pp.1-2.
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sarcoma, lung cancer, pancreatic cancer,

leukemia, genital and common

warts.
To date, malignant melanoma appears to be the most promising
DETOX^ application.

"In October 1987, Ribi ImmunoChem Research,

Inc.

signed a $1 million, five-year research agreement with the University of
Southern California to sponsor Dr. Malcolm Mitchell's work with melanoma
cancer vaccines in return for commercial rights to certain products."^®
"Initially,

the work will focus on the use of a vaccine in cancer

treatment, but eventually it will include study of cancer prevention ."11
In Phase I testing, Dr. Mitchell has found that by combining
DETOX* with existing melanoma vaccines and injecting patients:
— > ten out of seventeen patients with spreading melanoma showed
signs that stimulation of their immune system to battle
melanoma had been achieved;
— > eight of those patients showed measurable reduction in their
tumor sizes— two experienced complete tumor regression,

three

experienced reduction of tumor size by at least 50%, and three
experienced minor tumor regression.
— > the results were better than those achieved using conventional
chemotherapy, and without significant side effects. 1 %

Having satisfied precllnical and Phase I human clinical tests.
10 Rlbl Immunochem Research.

Inc., 1987 Annual Report, p.5.

"Rlbl Signs Pact with USC Cancer Research," Missoulian. 15
October 1987, p. 1 2 .
Rlbl Immunochem Research.

Inc., 1987 Annual Report, pp.5-6.
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DETOX* Is currently undergoing Phase II trials.

Pending more melanoma

patient tests, by the end of 1988 DETOX^ should enter Phase III trials.
Finally, as a genital and common wart therapeutic, DETOX* has entered
Phase I of human clinical testing.

2.

The Products— OVAMID*.

cancer agent.

OVAMID* is the Company's second anti

Developed in 1983, OVAMID* might provide relief from

ovarian, cervical, colorectal and bladder cancers.

Unlike the cancers

targeted for DETOX* treatment, cancers targeted for OVAMID* treatment
are not solid masses: rather, they spread within human cavities.
intralesional injection of any type is thus impossible.

Direct

Accordingly,

OVAMID* has been developed as a soluble product which can be used to
bathe the tumor cells within body cavities.
OVAMID* is currently undergoing Phase I trials of ovarian cancer
patients to evaluate the product's safety.

"Preliminary reports

indicate that treatment with OVAMID* has been tolerated by most
patients and no adverse side effects have been seen.

Reports also

indicate that the therapy has at least halted tumor growth in some
patients,

indicating that OVAMID*'s activity may stabilize the

disease."13

3.

Tb# Products— MPL*.

Monophosphoryl lipid A (MPL*) is one of Ribi

Immunochem's three proprietary adjuvants.

Although the adjuvant is a

key DETOX* and OVAMID* ingredient, alone M P L * Is also a powerful
stimulator of non-specific resistance to infection.

In particular, the

13 Ibid.
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adjuvant might prove effective protection against infections including:
malaria. AIDS, hepatitis A and B, certain forms of septicemia, and other
infections plaguing patients whose immune system is compromised
(chemotherapy/burn/radiation patients, and the elderly).
In 1987, "Ribi Immunochem Research,

Inc. signed an agreement with

the U.S. Army Medical Research and Development Command for the
evaluation and testing of Ribi products MPL* in a malaria vaccine.
Ribi's product MPL^ is being considered a way of making the vaccine
more potent."14
In March 1987, Ribi ImmunoChem Research,

Inc. "signed an evaluation

and option agreement with Baxter Healthcare Corporation to study M P L ^
in a limited area of infectious disease prevention."!®

Under the terms

of the agreement, Ribi will receive monthly payments from Baxter during
the option period and will provide the material M P L * to Baxter for the
studies.
MP L * "is expected to enter Phase I clinical trials in 1988 as a
malaria vaccine adjuvant and also for use prior to high-risk surgery as
a stimulator of non-specific resistance to opportunistic infections." 1 ®

4.

The Products— RIBIGEN*.

In 1983, Ribi ImmunoChem Research,

Inc.

received full governmental approval to distribute RIBIGEN®, a highly
effective commercial anti-tumor veterinary product.

RIBIGEN® was

14 "Rlbl To Test Products for Malaria Vaccine," Missoulian, 22
October 1987, p.15.
1® Ribi Immunochem Research,

Inc., 1987 Annual Report, p.4.

1® Ribi Immunochem Research, Inc., 1987 Annual Report. Company Profile
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Introduced to treat eye cancer In cattle and sarcoid tumors in horses.
"Cure rates of 90% in horses and 6 6 % in cattle, regardless of the tumor
size treated"17 created widespread attention.
Initial consumer reaction to RIBIGEN® was encouraging.
marketing of the product in 1983 resulted in $30,000 sales.
sales of the product increased 449% over 1983 sales.
remained constant, and Ribi ImmunoChem Research,

Test
In 1984,

1985 sales

Inc. negotiated an

exclusive marketing agreement with Fort Dodge Laboratories, a major
worldwide pharmaceutical distributor.

The agreement did not increase

sales however--1986 RIBIGEN® sales dropped dramatically (96%), a problem
created by Fort Dodge's failure to honor product purchasing agreements.
Seeking a network of distributors, Ribi ImmunoChem successfully doubled
RIBIGEN® 1986 sales in their 1987 marketing effort.

5.

The Products— Research Products.

Ribi Immunochem Research, Inc.

"markets a line of 49 research products worldwide to industrial,
governmental, and academic laboratories."^®

"Many researchers have

described the Company's microbial adjuvants (research products) as the
best available, both for increased efficacy and reduced side effects." 1 ®
With the exception of investment income, Ribi's research products
generate most of the Company's revenues.

In fact, the past two years

(1986, 1987) research products have generated approximately 30% of total
Company revenues.

(See Table 2).

17 Ribi Immunochem Research,

Inc., 1983 Annual Renort. p. 2 .

18 Ribi Immunochem Research.

Inc. , 1987 Annual Report, Company Profile

19 Ribi Immunochem Research,

Inc. , 1988 Annual Renort. p. 1 0 .
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D.

Federal Regulation.

Depending whether Ribi’s products are intended

for human or veterinary use, different federal agencies regulate the
products' manufacturing, testing, and marketing phases of product
development.

For human biopharmaceutical products, the Federal Drug

Administration monitors precllnical studies,

filing applications, human

clinical trials, and product license application approval.

For

veterinary products, the U.S. Department of Agriculture monitors product
development.

If either human or veterinary products are intended for

foreign distribution, often foreign regulating agency procedures must be
satisfied.
"The process of seeking and obtaining FDA approval of a new product
takes a number of years and often involves substantial expenditures " 2 0
Nils Ribi, Ribi Immunochem Chairman of the Board, recently stated.

"We

estimate it takes at least eight years for our human health care
products to move from the laboratory to the consumers."2 *
Prior to approval of a Product License Application (PLA), a series
of tests must successfully be completed.

First, precllnical product

tests must be conducted in the laboratory and on animals.

The tests

results are submitted to the FDA with an Investigational New Drug
application (IND).

If the IND is approved, human trials may commence.

Three phases of human clinical trials are required.

Phase I trials

test maximum tolerated dosage and possible side effects on human

20 Ribi Immunochem Research.
31 December 1986, p.11.

Inc., SEC Form 10-K (Annual Report).

21 Opening address by Nils Ribi for dedication of Ribi ImmunoChem
Research, Inc. new research facilities, Hamilton. MT, 19 March 1988.
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volunteers (cancer patients in the case of anti-tumor agents).

Phase II

trials examine the most effective dosages and schedules of
administration for specific ailments common to groups of patients.
Phase III trials Involve wide-scale studies to examine patient group
response rates to the biologies.

Once all phases of trials are

successfully complete, a Product License Application may be submitted to
the FDA.

If the PLA Is approved, the product may then be commercially

distributed.
USDA testing of veterinary products usually Is less time consuming
and less expensive than FDA testing.

Accordingly,

"potentially faster

product approval through the USDA makes the animal health Industry
highly competitive ."22
On June 22, 1987, the FDA changed their strict drug approval
policies.

Prior to the June decision, drug manufacturers "could make

experimental drugs available free of charge, on a compassionate basis
for gravely ill patients."23

with the policy change, under certain

conditions drug manufacturers can charge patients a fee for recovering
the drug's manufacturing costs.
Rlbl Immunochem Research,

The change Increases opportunities for

Inc. and other drug research firms to expand

their patient test base, while recovering some of the expensive research
costs.

E.

Patents and Protection.

Ribi ImmunoChem Research, Inc. "maintains a

Ribi Immunochem Research.
31 December 1986, p.12.

Inc., SEC Form 10-K (Annual Report).

22 Marilyn Chase. "FDA Rule Changes May Rush New Drugs to Very Sick
Patients," Wall Street Journal. 5 October 1987, pp.l and 22.
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Strong patent position (with 13 U.S. and 94 foreign patents issued or
allowed, and 6 U.S. and 54 foreign patents pending) for the manufacture,
composition and use of its products and

t e c h n o l o g y . " 2 4

To maintain a competitive position within the industry, biotech
firms must develop patentable products and/or processes.

Ideally,

patents protect firms against piracy, and generate compensation for
exchanges of products or processes.

In practice however,

"there is no

assurance that others may not independently develop similar technology
or that secrecy will not be breached."25
To reduce information piracy and improve licensing revenues.
Immunochem Research.

"Ribi

Inc. maintains an active trademark protection

program in the U.S and those countries where it expects to market its
products."26

Additionally, all employees are sworn (through employment

agreements) to not disclose proprietary information for two years
following their separation from the Company.

P.

Staffing.

According to Nils Ribi. "since incorporation in 1981,

Ribi Immunochem Research,
people."27

Inc.'s staff has grown from four to fifty

Of the fifty, more than half are directly involved in

research and development.

24 Ribi Immunochem Research,

Inc., 1987 Annual Report. Company Profile

25 Rlbl Immunochem Research.
31 December 1986, p.13.

Inc., SEC Form 10-K (Annual Report).

26 Ribi Immunochem Research,
31 December 1986, p.13.

Inc., SEC Form 10-K (Annual Report).

2"^ Nils Rlbl dedication address of new facility, Hamilton, MT.
19 March 1988.
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Nils Rlbi has long stressed the importance of quality research
conducted by leading scientists to assure a competitive position within
the biotechnology industry.

He has also supported the Importance of

staffing leading business officials experienced in pharmaceutical
marketing.

Accordingly, Ribi ImmunoChem Research,

Inc. has employed

research scientists (many Ph.D.s) and experienced business professionals
to develop the products and bring them to market.

Figure 1 on the

following page depicts the Company's organizational structure.
One of the strengths of Ribi ImmunoChem's leaders has been their
ability to recognize their own limitations.
Ribi and later his son Nils,

Beginning with Dr. Edgar

the two leaders never risked Company

success by involving themselves in operations where they were not
qualified.

If they were not expertly experienced in specific facets of

the Company's operations, they employed someone who was.
In 1987, Nils Ribi

"urged the board to find a new president for

Ribi ImmunoChem Research.
death of his father.'*28

Inc. when he was named chairman following the
Speaking in his own behalf. Nils Rlbi said,

"I

think I am a very good start-up company person, a very good organizer, a
good systems man.
build it.

I can put together a company In the early stages and

But this gets very complex.

I don't want to let an ego get

in the way of the success of the Company."28
Supporting Mr. Rlbi's recommendation, the Company's board embarked
on a lengthy search for a new president and chief executive officer.

28 "Rlbi President Fits With Plans for Growth Era," Missoullan. 5
July 1987, p.B-1.
28 Ibid.
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July, 1987, they announced their pleasure to employ Mr. Robert Ivy, an
experienced (30 years) pharmaceutical and marketing manager with
companies Including G.D. Searle, Scherlng A.G., and Revlon Health Care.
The last four of the thirty years, Mr. Ivy headed a company involved In
cancer-related contract research.
In March 1988, Nils Rlbi and Bob Ivy announced

"the Company's plans

to triple Its size to about 150 employees In the next five years."30

As

a means to generate a good pool of local Job applicants, the Company
leaders also announced that they would provide more than $60,000 to fund
graduate research at the University of Montana In the 1988-89 academic
year.

Additionally,

"the University will appoint selected Rlbi

scientists to lecture In microbiology, mlcrochemlstry, and chemistry
courses at Rlbi's expense."31

G.

Facilities.

Prior to Incorporation. Dr. Edgar Ribi sketched plans

for his company while continuing adjuvant research In a renovated garage
In Hamilton, Montana.

As the needs of production, research, and

development grew, the Company (over the last seven years) expanded its
facilities in phases.

To date, Rlbi ImmunoChem Research,

Inc. occupies

40,000 square feet of high-technology facilities located on 35 acres in
Hamilton.
A recently completed $2.7 million expansion project ($1.6 million
for construction, $1.1 million for new equipment) doubles Ribi

3® Theresa Johnson. "Ribi to Help Fund Graduate Research at UM,
Missoullan. 20 March 1988, pp.1-2.
31 Ibid.
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ImmunoChem '9 production area and triples laboratory space for research
and development.

"The added space will allow the company to

significantly increase production of Its proprietary anti-tumor agents
DETOX^ and OVAMID^ in order to maintain adequate supplies for expanded
clinical trials."32

Additionally, the added space will be used for

production of antigens for use in cancer vaccines.

H.

Financial Condition.

Company success hinges on moving products

successfully through clinical testing.

To date, one veterinary product

(RIBIGEN®) has received approval for commercial distribution.

DETOX*,

a potentially more profitable human health care product, has been
undergoing testing since 1983.

Although clinical approval of the

product may never come. Ribi ImmunoChem Research,

Inc. must generate

capital to fund continue research and development.
The Company generates capital through operating, investing, and
financing activities.

Investment income earns the majority of the

Company's operating capital, followed by product sales, contracted
services, and licensing (see Figure 2).

Liquidated investment

securities have provided in excess of $3 million dollars in 1986 and
1987, while stock proceeds have generated $26,181 for the same period.
Although the Company has not generated sufficient revenues to earn
profits yet, Ribi ImmunoChem Research,

Inc. has expanded laboratory

facilities and acquired new laboratory equipment without incurring long
term debt.

Ribi ImmunoChem officers expect not to be profitable until

Ribi ImmunoChem Research,

Inc., 1987 Annual Report, p.10.
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the Company's expanded research and development effort moves the first
human health care product to market.

(The following discussion refers to Rlbi ImmunoChem Research,
Inc.'s

1.

financial statements included in the Appendix).

The Income Statements (Statements of Operations).

Research,

Inc. has not been profitable.

management has recorded losses.

Ribi ImmunoChem

Every year except 1986,

1986 would also have also been

unprofitable, however life insurance proceeds (from Edgar Rlbi's policy)
were significant enough to generate a Company profit.
Salaries and research and development expenses comprised eightyeight percent of the Company's 1987 expenditures, compared to eightyseven percent in 1986 and seventy-three percent in 1985.

Salaries is

the Company's single most expensive item, accounting for forty-four
percent of 1987's expenses.
Product sales have grown steadily since 1981, however investment
income has generated the most Company revenue.

Total revenues have not

been sufficient to produce annual profits— in 1987, total revenues were
fifty-nine percent of total expenses.

Figure 2 charts revenue trends of

the three most significant Income sources.

As a supplement. Table 2

details the revenue breakdown of all income sources for the three-year
period 1985 through 1987.

2

The Balance Sheets.

Most of Rlbi ImmunoChem's total assets are

marketable security investments, purchased with proceeds from public

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Stock sales In prior Issuances.

In 1986 and 1987. investment securities

had represented over two-thirds of the Company's total assets, an
unusually high percentage.
Company assets have grown rapidly since 1981.

With first year

total assets of $1,984,422, the Company's assets have grown to
$15,586,206.

Although the assets have grown, the stockholders equity

per share has fallen from $2.09 in

1981 to $1.74 in 1987 (see Table

1).

1987 plant expansion and equipment purchases have been paid with
cash

Using 1985 cash flows contributed by common stock proceeds of $11

million, and liquidated investment securities of over $3 million in 1987
and 1986, the Company has generated adequate cash flows to cover
expansion and operations.

Table 4 traces Ribi ImmunoChem Research.

Inc.'s historical cash flows from 1985 through 1987.
Table 4 also includes annual (pro forma) cash flow projections.
According to the table, if:
— > Ribi ImmunoChem triples its labor force over the next five
years as announced.
— > product sales do not improve (assuming sales will not improve
significantly until a new product is approved for commercial
distribution).
— > stock issuances yield the same proceeds as 1987.
-> and the Company is forced to continue the recent trend of
liquidating investment securities,
Ribi ImmunoChem Research.
securities) by 1991.

Inc. will run out of cash (and investment

However, if the Company chose to not triple the

labor force in the next five years, and sales and stock proceeds
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remained the same, the Company would only need to liquidate half its
investment securities to generate a positive cash flow in 1991 (see
Table 6 ).

Ribi ImmunoChem has avoided debt, and is backed by

considerable short-term investments.
position has been strong.

Accordingly,

its liquidity

Table 1 tracks the company's liquidity

position through current ratio analysis.

Although the table does not

predict the Company's ability to pay off future debt, liquidity would
drop if (as predicted) investment securities were sold to fund future
operations.

3.

Shareholders' Equity.

At the close of 1987, Company records listed

approximately 1,444 shareholders.

Of the shareholders. Executive Life

Insurance is one of the largest, owning over 600,000 shares.

Ribi

officers, employees, and other persons providing important Company
services share in Rlbi ImmunoChem Research,
stock grant program and a stock option plan.

Inc. ownership through a
Approximately eleven

percent of Company stock is held in this manner.
Currently the Company's Board of Directors, has authorized Ribi
ImmunoChem management to sell 20 million common shares (at $.001 par).
Slightly more than 8.5 million shares have been issued.

The gap between

the authorized celling and number of shares issued provides considerable
opportunity for investors to purchase Ribi stock.
Table 3 compares important shareholder Information.
ImmunoChem has not paid dividends to shareholders.

First, Ribi

Second, the number

of shareholders has grown steadily since the first public offering.
Third, each year (but one) the shareholders have incurred losses per
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Share.

Finally, the Company's stock price is volatile, attracting only

the most speculative investor

According to April 1987 Standard and

Poor’s PTC Stock Reports (vol.53. no

41. sec 30). Rlbi ImmunoChem*s

beta coefficient is 2 .8 6 .

Figure 2
Ribi ImmunoChem Research, Inc.
Major Revenues

0.8 -4

0 .4 -4

0.1

1981

1985

1982

p r o d u c t sdtes

source; Ribi ImmunoChem Research.

cntrct srvcs

1986
Tnvst

Inc. income statements: 1981— 1987
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Table 1
Rlbi ImmunoChem Research, Inc.
Financial Ratios
Ratios/Years:

1987

Profitability:
ROA
ROE

(.070)
(.070)

.003
.003

Liquidity:
Current ratio

19.73

114.96

1986

1985

1984

1983

1982

1981

(.030)
(.030)

(.052)
(.053)

(.058)
(.059)

95.09

24.29

60.89

32.08

32.02

(.073) (.081)
(.074) (.107)

Indebtedness:
Debt/equity

.039

.008

.009

.030

.013

.026

.324

Shareholders
Equity:
Equity/share

1.74

1.87

1.86

.78

62

1.49

2.09

source:

calculations based on extrapolation of financial figures
provided in Rlbi ImmunoChem Research, Inc.'s financial
statements (1981-87)

Table 2
Rlbi ImmunoChem Research, Inc.
Detailed Revenue Breakdown

Year Ended December 31

Research products
License & option fees
Investment Income
Contract services
Animal prods. (RIBIGEN®)
Laboratory Animals
Other
Total Revenues

1987
Amount

%

1986
Amount

%

29

$ 455,276

28

6

12,000

1

$ 450,863
92,903
866,548
124,136
12,403
12,507
4.807

8
1
1
__ 2

$1,564,167

100

source: Rlbi ImmunoChem Research,

55

1,106,708
25,046
5,732
13,494
4,743

69
2

1

—

$1,610,999 1 0 0

Inc., 1987 Annual Report
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1985
Amount

%

$ 182,259

19

595,956
1,225
160,000
28,346
186

61
16
3

‘tm

$979,972 1 00
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Table 3
Rlbi ImmunoChem Research,

Inc.

Shareholder Data
Year ended Dec,,31: 87
Book value
Stock Prices:
Hig
Low
Beta
Equity/share
Earnings/share

NA
11 3/8
3

85

84

83

82

81

1.87

1.86

.78

.62

.66

.29

5 1/4

2 1/2
1 1/8

11

1/2

5

10

6

8

4

3

3 1/8

1

1/8

1/8

2.86

1 .74
( .13)

A v e .number of
shares outstanding
(millions)
8.6
Dividends paid

86

0

1.87
.01

(.06)

.78
(.08

.62
(.07)

1.49
( .1 1 )

2.09
( .2 2 )

8.6

7.5

3.4

3.1

2.6

.72

0

0

0

0

0

0

1.86

source:
Rlbi ImmunoChem Research, Inc. financial statements; Standard
and Poor's OTC Stock Reports (vol. 53, no. 41, sec . 30). 10 April 1987.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

27

Table!
RIBI IWJNOCHW RESEARCH. INC
Pro Forma Cash Flows
(Thousands)

1987

1985

1986

Cash Flows from Operating Activities:
Net Income (Loss)
Oepreciation/Amort ization
Accounts Receivable
Accrued Interest Receivable
Inventories
Other Current Assets
Acooints Pebble
Accrued Expenses
Deferred Income

(479)
146
(33)
(255)
41
(22)
(21)
11

55 (1.086) (1,790) (2.496) (3.198) (3.902)
135
147
300
300
300
300
9
0
0
0
0
(4)
(402)
472
0
0
0
0
17
(34)
0
0
0
0
(52)
22
0
0
0
0
(95)
324
0
0
0
0
62
146
0
0
0
0
6
0
0
0
0
(6)

Net Cash Flows from Operating Activities

(612)

(316)

Cash Flows from Investing Activities:
Capital Expenditures
Payments for Other Assets
Change in Investment Securities

(161)
(102)
(10.694)

(204) (2,175)
(49)
(96)
2,714
425

Net Cash Flows from In w tin g Activities

(10,957)

2,461

Cash Flows from Financing Activities:
Proceeds from Issuance of Stock

11,115

Net Increase (Decrease in Cash)

Cash-aaglmlng of Year
Cash— End of Year

32

1988

1989

1990

1991

(1.490) (2.196) (2,898) (3,602)

0
0
1000

0
0
2200

0
0
2855

0
0
1500

(1,846)

1,000

2,200

2,855

1,500

19

7

7

7

7

7

(454)

2,164

(1,807)

(483)

11

727

273

2,437

630

147

$273

$2,437

$830

$147

$158

(36) (2.095)
158

122

$122 ($1,973)
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CHAPTER IV:
THE MARKETS

Ribi ImmunoChem Research.

Inc.

is engaged In the research and

development, production, and marketing of adjuvant products and
technology.

The Company believes that by developing safe, affordable,

and effective adjuvant products.

It will replace conventional cancer and

Infectious disease health care methods which are too often unsafe
(toxic), disabling, or not affordable.
In its corporate strategy,

the Company has identified two human

health care markets to aggressively pursue;
cancer.

infectious disease and

Both are perceived to offer extreme profit potential, and both

are prime adjuvant targets.

Nils Ribi. Board Chair, speculated In

October 1987 that the cancer vaccine market could be $500 million.
Infectious diseases, on the other hand,
billion."33

"could be as high as $3

Supporting Rlbi's estimate, a recent report published by

the 1987 Biotechnology Data Group estimated the market for new
infectious disease adjuvant vaccines could "reach $ 1 - 2 billion
worldwide."34
Generally speaking,

it is impractical to approximate (in dollars)

the total size of Infectious disease and cancer markets.

Since adjuvant

technology for the proposed Company applications is still undergoing
testing and development, specifying costs associated with dosage.

33 Personal interview with Nils Ribi, Board Chair, Ribi ImmunoChem
Research. Inc.. Hamilton, Montana. 23 October 1987.
34 1987 Biotechnology Data Group. "Drug Delivery/Formulation," Issues
and Commentary Reports. (Cambridge, Massachusetts, 1987), pp.3-5.
28
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product effectiveness, and delivery methods, etc.
However,

is difficult.

in order to gain a sense of the market magnitude for adjuvant

applications, Chris Dyzynski

(Ribi ImmunoChem's Marketing Manager) has

ventured potential market guesses for the following infectious disease
and cancer applications.

A.

Infectious Diseases.

Ribi ImmunoChem scientists are researching two

infectious disease applications: developing their adjuvants for
combination with new generation vaccines, and using their adjuvants to
enhance high-risk patients' non-specific resistance to a variety of
infections.

1.

The potential market for each application is tremendous.

Infectious Diseases— Vaccines.

Vaccines using Company adjuvants

could create tremendous sales potential.

To date, Ribi ImmunoChem is

collaborating with select researchers in an effort to improve or
discover new vaccines that could treat and prevent malaria, hepatitis,
AIDS, tetanus, and genital warts.
It is estimated that 78 million people suffer from malaria each
year.

Most of the victims are from third world nations, often too poor

to afford vaccine treatment that is usually not effective anyway
Accordingly, Ribi ImmunoChem Research,

Inc. is currently providing the

U.S. Army Medical Research and Development Command Company adjuvants for
evaluation and testing in new, more effective, affordable vaccines.
an estimated per treatment cost of $.30,

At

the annual malaria vaccine

market could exceed $23 million.
Hepatitis is a viral infection of the liver caused by contact with

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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contaminated blood.

According to a 1987 Wall Street Journal article,

some 300,000 people get hepatitis each year in the U.S.; there are more
than 250 mi il ion carriers world-wide and two million associated deaths

annually."35

The market for hepatitis vaccine and tests during 1988 has

been estimated at $ 2 0 0 million.
Depending on the source, national estimates of the number of actual
AIDS cases and number of people exposed to the AIDS virus vary.

Ribi

ImmunoChem estimates 42,000 people suffered from AIDS in 1986, while
three million people were likely exposed to the virus.

Estimating

treatment of $ 2 . 0 0 per patient exposed to the virus yields a potential
AIDS market of $ 6 million.
developed,

Further, until an AIDS treatment is

the incidence of the disease will grow exponentially in

future years, rapidly expanding the market potential.
Tetanus effects over seven million victims nationally each year.
Ribi ImmunoChem Research,

Inc. estimates that a new vaccine treatment

(which Includes Company adjuvants) could create a market in excess of
two million dollars each year.
Finally,

"genital warts is believed to be the fastest spreading

sexually transmitted disease in the United States,
estimated one million persons annually."3®

infecting an

According to Hr. Dyzynski's

treatment estimates ($75.00 per case), the infliction could create a
potential D E T O X * annual market of $75 million.

3® William Bulkeley, "Biogen Gets Broad Patent on Antigens For
Hepatitis B Used By Other Firms," Wall Street Journal. 4 December 1987.
35 Rlbi ImmunoChem Research,

Inc., 1987 Annual Report, p. 8 .
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2.

Infectious diseases— Non-specific Resistance and Ianune System

Compromised Patients.

Ribi ImmunoChem's scientists are exploring other

infectious disease adjuvant applications.

They are evaluating adjuvant

applications M P L ^ that could assist high-risk patients with fending off
infection.

In particular,

the scientists are examining the ability of

the Company’s adjuvants to stimulate non-specific resistance to
Infection in pre-operative patients, and in patients whose immune system
is compromised.
Ribi ImmunoChem Research.

Inc.'s

marketing department has

estimated that over eight million patients admitted to U.S. hospitals
each year for surgery are prone to infection.

The chance that Rlbi's

adjuvants could prevent pre-operative infections might create a market
of over $800 million annually.
If adjuvant applications are effectual in preventing infection
amongst immune compromised patients (the elderly, or
burn/radiation/chemo-therapy patients), the potential market is also
staggering.

In total, patients whose immune system is compromised could

create an annual market in excess of $ 1 0 0 million.
Septicemia is a form of blood poisoning often acquired through
patient exposure to hospital-borne (gram negative) bacteria.
to Ribi ImmunoChem Research Inc.'s 1986 Annual Report,

According

"in the United

States, more than 200.000 people annually develop septicemia in the
hospital, and about half die regardless of therapy.

The number of

persons worldwide considered at risk for hospital-acquired infections
has been estimated as high as a half-billion."3?

37 Rlbi ImmunoChem Research.

If the estimated

Inc., 1986 Annual Report, p. 8 .

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

32

treatment cost per case Is

$500 (based on Company estimates), the

national septicemia market

could be as high as $ 1 0 0 million.

B

Human Cancer Applications.

health.

Cancer is a terrible threat to human

The American Institute for Cancer Research specified,

approximately 1,000,000 Americans will develop cancer.
seconds,

Every 65

someone dies of cancer in America, and this year almost 500,000

people will die of the disease.
cancer,

"In 1987,

the second leading

One out of every five deaths is from

cause of death in this country."^®

Certain human cancer forms are best suited for Ribi ImmunoChem
adjuvant treatment.

Each form creates a unique market.

Following are

the primary DETOX^ cancer markets the Company explores: malignant
melanoma,

lung cancer,

leukemia, and pancreatic cancer.

Additionally,

potential OVAMID^ market applications include: superficial bladder
cancer, colorectal cancer, and ovarian cancer.

1.

Human Cancer Applications— DBTOX*.

Malignant melanoma is usually

characterized as a dark-pigmented skin tumor.

"2 2 , 0 0 0 cases were

reported in 1985 that resulted in approximately 7,400 deaths
nationwide."39

Treatment of every reported case could yield a potential

market of $ 6 6 million (based on an estimated $3000 cost per treatment).
Lung cancer effected 150,000 U.S. people last year.

Assuming a

level annual trend of case reports, a total market for this form of

3® American Institute for Cancer Research, Dietary Guidelines To Reduce
Cancer R i s k . (Washington, D.C.: Government Printing Office, 1987), p.2
39 Rlbi ImmunoChem Research,

Inc., 1986 Annual Report, p. 6 .
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cancer could exceed $400 million.
Leukemia is a disease involving the uncontrollable increase of
leukocytes (white blood cells).

According to Ribi market research,

"24.000 new cases are reported each year, and 16,000 deaths annually.
According to Company treatment estimates,

the annual leukemia market

could equal $72 million.
"Pancreatic cancer has a high mortality rate because it is
difficult to detect and has often spread to other organs before it is
diagnosed.

25,000 new cases were reported in 1 9 8 4 . Accordingly,

Ribi ImmunoChem Research,

Inc. estimates the potential market is $75

million.

2.

Human Cancer Applications— OVAMID*.

The markets created by the

other common forms of cancer targeted for OVAMID* treatment are also
staggering.

According to Rlbi's market research, potential markets for

colorectal cancer could exceed $400 million, bladder cancer $100
million, and ovarian cancer $50 million.

3.

Human Cancer Applications— Strategic Available Markets.

Although

potential total cancer markets can be estimated, the market share Rlbi
ImmunoChem Research,

Inc. can capture is considerably less.

shrink the Company's potential markets.
administered in unison with other agents.

Two factors

First, often the treatment is
In those cases where a

vaccine is formulated using other agents. Ribi ImmunoChem Research,

40 Ibid.
41 Ibid.
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would only have right to revenues equaling the proportion of Company
adjuvant products used.

Secondly, Ribi ImmunoChem cannot expect to

supply all of the needed therapeutics or preventatives.

Limited

physical production constraints will permit only predictable levels of
production.
Accordingly, Ribi ImmunoChem Research.

Inc. has estimated

"strategic available markets" that the Company could capture annualIv.
D E T O X * cancer applications could capture 40% of the U.S. market ($200
million).

For genital warts, on the other hand, DETOX* could be

applied to ten or twenty percent of U.S. cases ($10— 20 million).
OVAMID* has been targeted to capture five to fifteen percent of U.S.
markets, or $15 million.

C.

Animal Cancer Applications.

Ribi ImmunoChem Research.

primarily concerned with exploring human health markets.

Inc. is now
Initially,

however, the firm was incorporated to "engage in the research,
development, production and marketing of biomedical agents, which are
designed to activate the human or animal immune system in an effort to
combat diseases.
Animal health care is no longer the Company's primary market
interest.

According to Nils Ribi.

"although we are phasing out animal

health care products because they are not as profitable as the human
health care products, we will not ignore animal application

Ribi ImmunoChem Research,

Inc.. 1981 Annual Report, p.l
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opportunities discovered through human application research "*3

D.

Research Products.

adjuvants for research.
ready-to-use

Internationally, scientists seek Rlbi's
The Company has Introduced their adjuvants as a

"Ribi Adjuvant System."

"RAS provides researchers with a

convenient and highly effective adjuvant delivery system for vaccine
testing In comparison to the previous research adjuvants."44
The research market supplements Rlbi revenue.

Many industrial,

academic, and governmental researchers consider Rlbi's adjuvants the
best available.

Marketing 50 adjuvants for research, 1986 and 1987

research product sales comprised near 30% of total Company revenues.
(Table 2 displays a comparison of the Company's revenues from 1985
through 1987).

43 Personal interview with Nils Ribi. Board Chair, Ribi ImmunoChem
Research, Inc., Hamilton, MT, 23 October 1987.
44 Rlbi ImmunoChem Research,

Inc., 1986 Annual Report, p. 10.
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CHAPTER V:
INDUSTRY’S MAJOR COMPETITORS

A.

Competition.

Intense.

Competition in the human blopharmaceutical Industry Is

Scientists worldwide are racing to discover new generation

vaccines plus more effective, non-toxic, and cheaper cancer and
infectious disease treatments.

They are driven by dreams of success and

tremendous profits.
The industry is made up of competitors of various size and
therapeutical approach.

From private to public,

international to local,

worldwide interest in human health care attracts diverse competitors.
Generally,

the more notable competitors include: private research (large

pharmaceutical companies, smaller biotechnology companies, private
academic institutions);

public research (hospitals, public academic

institutions), government research (foreign and U.S.), and more
commonly,

collaboration between two or more competitors.

collaborations link capital with opportunity.

Often the

Accordingly, the most

small biotech firm could prove most competitive with financial backing
from a heavily capitalized source.
According to Ribi,

it is not necessarily financial strength,

research facility size, or manpower that determine the level of industry
competition.

Rather,

it is research experience— patentable research

experience that produces non toxic, effective, and affordable products.
Exploiting the Company's research strength. Nils Ribi described the
Company's competitive strategy,

"we intend to stay a step ahead of our

competitors, and maintain our leadership position by continuing quality

36
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research and development of new adjuvants and applications for
adjuvants."45
Nils Ribi contends that one measure of research experience is to
examine a firm's scientific publications and presentations;

the other is

to note the number of patents that have been awarded.
Ribi ImmunoChem Research.

Inc. maintains two bibliographies of

published Company research and presentations.

One bibliography (the

Company's) documents 50 research publications and thirteen national and
International presentations completed between 1982 and 1987; the other
(Edgar Rlbi's) lists 185 research publications completed between 1948
and 1985.

The majority of the publications and presentations were

either written or presented by Edgar Ribi.

Often he co-authored the

publications with other Company, national, or international research
scientists.
Although Rlbi ImmunoChem scientists have published numerous
research articles, Nils Ribi advised that the extent of publication has
not weakened the Company's competitive stance.

Mr. Rlbi remarked that

by patenting new adjuvant applications or technology before publishing,
the Company is protected by law from piracy.
Ribi ImmunoChem is also in a strong patent position.

According to

the Company's 1987 Annual Report. "13 U.S. and 94 foreign patents have
been issued or allowed, with six U.S. and 54 foreign patent applications
pending).”4®

45 Personal interview with Nils Ribi, Chairman of the Board, Ribi
ImmunoChem Research, Inc., Hamilton. NT, 13 November 1987.
4® Ribi ImmunoChem Research,

Inc., 1987 Annual Report. Company Profile.
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B.

Industry Segmenta.

The therapeutical approaches to providing relief

from or prevention of cancer have created industry segments.
Immunotherapy, chemotherapy,
common therapies today.
than others.

radiation therapy, and surgery are the most

Each has inherent limitations, some more severe

The latter three approaches "usually have serious side

effects and leave the body defenseless against a recurrence of the
disease."47

Traditional methods of immunotherapy, on the other hand,

experience limited success.
Because current approaches are not effective, produce undesirable
side effects, or are too toxic, many biotechnology companies are
exploring new immunotherapeutical cancer treatments and vaccines to
complement current approaches.

"Such immunotherapy, as it's called,

would complement the standard therapies: surgery, chemicals (or
chemotherapy) and radiation."48

Research and testing of molecularly

and genetically engineered adjuvant technologies are drawing
considerable attention.

According to the 1987 Biotechnology Data Group,

"a renewed interest in vaccine development has been inspired by the
advent of new biosynthesis and molecular engineering technologies which
offer a new range of potentially safe and effective products."49

{Table

5 identifies major biotechnology competitors by their applications, and
an estimated market share position they may control).

47 Ribi ImmunoChem Research,
Investors. January 1988, p.2.

Inc., Research:

Ideas for Today's

4® Jerry Bishop. "Successes in Lung Cancer Vaccine Trials Raise Hope
for Future of Immunotherapy," Wall Street Journal, (eastern edition),
16 September 1987, p.37.
49 1987 Biotechnology Data Group, "Drug Delivery/Formulation," Issues
and Commentary Reports. September 1987, p.3.
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Ribi obtains their adjuvants from molecular engineering.

Three of

the Company's proprietary adjuvants are extracted from endotoxin, a
highly toxic bacterium

According to Table 5, Ribi ImmunoChem Research,

Inc.'s cancer and infectious disease approaches are unique, creating
opportunity for tremendous earnings.

C.

Limitations to Industry Growth.

The human blopharmaceutical

industry can be "characterized as an emerging industry with multiple
technological frontiers.

Although regarded as a promising 'industry of

the future,' its potential is uncertain and growth could occur in many
directions."
The industry grows slowly.

It is regulated by a complex

intertwining of constraints:

innovation,

1.

Innovation presents a continual industry

Innovation constraints.

challenge.

liability issues, and cost.

The constant search for new ideas is challenged by

Innovative ability, quality research, specialized high-tech equipment,
capital,

"and to some degree, on how much more scientists are able to

learn about the elaborate workings of the immune system."31
to a 1906 business and medicine report,
explode into vaccines,

According

"before the biotech boom can

it must wait on the development of adjuvants.

Progress toward developing more effective adjuvants, however, has been

33 Arthur Thompson and A.J. Strickland. Strategic Management: Concents
and Cases. (Texas: Business Publications, 1984), p.102.
31 Delthia Ricks, "Vaccine Offers Hope in Melanoma Treatment," Los
Angeles Tim e s . 2 August 1907, Section II, p.3.
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9lOW”®2
Brainstorming and collaboration are methods of encouraging
Innovation.

Counter to historical industry trends, biotechnology

companies, governmental agencies, and higher education institutions are
sharing Information.

Their research, and In some cases, capital are

shared as they cooperatively develop new Ideas, technology and products.
The 1987 Biotechnology Data Group report Justified recent Industry-wide
collaborations,

"these barriers to entry (Innovation constraints,

liability issues, and cost) will necessitate collaborations between
small companies and market leaders to bring new technologies to market,
and support the costs of vaccine development and commercialization."®^
Rlbi ImmunoChem Research,

Inc. actively seeks partners to help

speed the Company's products to market.
Journal.

According to a 1987 trade

"Rlbl is collaborating with about 20 other biotechnology

companies.

Typically, the collaborators team up to test a new Ribl

adjuvant with synthetic vaccines produced by the other company."®*
Recently, a licensing agreement between a moderate size
biotechnology firm and a major pharmaceutical company have paid off.
Chiron (biotech firm) licensed their molecular technology to Merck and
Company.

Together they produced a new genetically engineered hepatitis

B vaccine which received federal application approval In 1987.

"Since

®2 Arthur Rlausner, "Booster Shots," In Vivo: The Business and Medicine
Report. November/December 1986, Number 19. pp.21-22.
53 1987 Biotechnology Data Group, "Drug Delivery/Formulation." Issues
and Commentary Reports. (Cambridge, Massachusetts: 1987), p.2.
®* Ricki Lewis. "Helping the Body Fight Cancer,” High Technology
Magazine. January 1987. p.l.
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approval a year and a half ago, the vaccine has generated U.S. sales of
$70 m i l l i o n , "55 according to Carolyn Patrick, Chiron Marketing
Representative.

(Ms. Patrick also stressed that Smith, Kline, and

French have recently begun marketing a similar hepatitis B vaccine in
Europe).
U.S. companies are not the only collaborators.

Capital rich

foreign companies have recently entered into agreements with domestic
firms, the industry leaders.

Promises of venture capital and/or royalty

payments have prompted several American biotech companies to cooperate.
The exchange assists U.S.

firms with delayed commercial payoffs and

funds continued research.
Particularly. Japan has begun acquiring U.S. biotechnology secrets
through licensing agreements.
article,

According to a recent Wall Street Journal

"Suntory (Japanese firm) has aggressively been acquiring U.S.

technology.

They engage in Joint research with Rockefeller University

on brain function and seeking drugs for the ills.
licensed from Biogen (U.S.

firm) the right to produce a natural cancer

fighter called tumor necrosis factor.
broad partnership with a U.S.

2.

Liability Ismues.

They have also

Finally, they are looking for a

(biotechnology) company."®®

Litigation, damage awards, and liability costs

are crippling the industry and forcing customers to pay Inflated health
care prices.

Until litigation relieves the industry of partial

®5 Telephone interview with Carolyn Patrick. Chiron Marketing
Representative, 10 February 1988.
®® "Gene Squad; Japanese Target Another Industry in which the U.S.
Holds a Lead." Wall Street Journal. 17 December 1987, p . 18.
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liability responsibility,

the industry's Increasing price trend Is not

expected to change.
Before a human health care product is granted application approval.
Federal Drug Administration requires it successfully pass four testing
phases.

The four phases of precllnlcal and clinical testing determine

the product's safety, dosage, and effectiveness.

Although commercially

available vaccines are thoroughly tested and their applications
federally approved, very Infrequently treatment using the product proves
threatening/fatal.
Hampered by increased liability expenses and reduced profits,
pharmaceutical corporations have been dropping from the industry.
1987 Biotechnology Data Group reported,

The

"approximately 3 million doses

of vaccines are administered on a yearly basis in the United States.
The number of vaccine-related injuries averages 75 cases per year.

The

resulting litigation, damage awards, and liability costs associated with
this low incidence of adverse reactions has forced several companies out
of the traditional vaccine

b u s i n e s s .

"57

(pigure 3 on the following page

illustrates the 1985 human vaccine market share position of the four
major U.S. pharmaceutical corporations).
The industry has been forced to dramatically increase product
prices to cover inflated insurance costs.

For example,

"the price of

DTP vaccine has Increased from $.37 per dose in 1982 to $11.22 per dose;

57 1987 Biotechnology Data Group, "Drugs DelIvery/FormulâtIon," Issues
and Commentary Reports. (Cambridge, Massachusetts: 1987), p.4.
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Figure 3
1985 Human Vaccine Market Share»
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Source:
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insurance costs may comprise 70% of the price."5*

Additional evidence

from the 1986 Business and Medicine Report suggests,

"that over $2

billion in liability suits have induced Lederle to raise its price from
seven dollars to over sixty dollars for a whooping cough vaccination."®^

3.

Cost and Profitability.

typify the industry.

Tremendous research and development costs

Sophisticated equipment, adequate facilities,

quality scientists, and competent business executives are available at
premium prices.

Operating and administrative expenses are predictable;

often income is not.

Further, FDA product testing delays sales at least

three years, but usually twice that long.
Survival in today's highly competitive biotechnology industry
depends on maintaining a positive cash flow until products receive
federal application approval.

At a minimum, a company should expect

delayed sales by three years for human health care products.
capitalization, positive investment returns,
contracted research, grants,

Adequate

loans, venture capital,

licensing, and other collaborations are

necessary to fend off bankruptcy if a firm lacks sales to support
operating costs.
Eventual FDA approval

(if granted) to market a cancer or infectious

disease product typically escalates a firm's profitability
substantially.

During the I980's. drug companies annual profits grew

58 1 9 8 7 Biotechnology Data Group. "Drug Delivery/Formulation.” Issues
and Commentary Reports. (Cambridge, Massachusetts: 1987), p.4.
Arthur Klausner. "Booster Shots," In Vivo: The Business and Medicine
Report. November/December 1986, No . 19. p.21.
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twelve to fifteen percent.
the companies'

Before the October *87 stock market crash,

third quarter net incomes had increased seventeen

percent.GO

D.

Industry Trends.

At best, cancer therapy trends are sketchy.

To

date, cancer therapy has been limited to chemotherapy, radiation
therapy, surgery, and traditional methods of immunotherapy.

None of the

therapies is totally safe nor do they always produce desired results.
According to a Science News report,

"survivors of childhood cancer have

an increased risk of developing bone cancer later in life, primarily
because of the use of radiation therapy and chemotherapy against the
original cancer."Gl

Additionally, a 1984 U.S. News and World Report

describing interferon treatment,
for cancer treatment stated,
disappointing.

the only biological compound licensed

"the experience with Interferon has been

The antiviral agent is found to help in some cancers

Including Kaposi's sarcoma, but showed little effect against the major
cancers— colon, breast, and lung."G2
Adjuvant cancer therapy may someday rule other therapies obsolete.
If successfully tested and licensed, adjuvants should not bald, scar, or
poison patients.

The reduced side effects should not only increase

patience response, but may also establish health care standards that

GO “Corporate Profits Surged 33% in 3rd Period, Before Market Crash."
Wall Street Journal. 9 November 1987, p. 20.
G1 R. Weiss, "Cancer Therapy Risks Assessed," Science N e w s . 12
September 1987, p. 165.
G2 Joseph Carey, "Fighting Against Cancer." U.S. News and World Report.
20 August 1984, p. 53.
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more toxic and maiming applications cannot meet.
Infectious disease therapy and prevention trends are also sketchy.
Although sketchy,

the market size is staggering (Ribi has estimated it

as high as $3 billion annually).
three trends:
side effects,

Firms pursuing this market follow

complementing existing therapies to reduce undesirable
improving existing therapies to keep pace with ever

changing viruses, and developing preventative cures for specific
infectious disease ailments.
Molecularly and genetically engineered adjuvants are gaining
considerable attention.

According to a recent report,

"a renewed

interest in vaccine development has been inspired by the advent of new
biosynthesis and molecular engineering technologies which offer a new
range of potentially safe and effective products.

Their ability to

improve the safety profile of existing products and create new vaccine
products for a host of serious infectious disease has the potential to
expand the vaccine market at least two-fold to reach $2 billion
worldwide.

1 9 8 7 Biotechnology Data Group,
"Drug Del ivery/Formulât i o n , Issues
and Commentary Reports. (Cambridge, Mass.: 1987), p.3.
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CHAPTER VI;
CORPORATE STRATEGY ANALYSIS

The following chapter discussion follows the outline process for
formulating competitive strategy presented by Michael E. Porter in
Competitive Strategy (The Free Press, New York:

A.

What Is the Business Doing Now?

1.

Assumptions.

1980, pp. xix-xx).

Virtually all of Rlbl ImmunoChem Research,

Inc.'s

corporate strategy centers on one critical assumption: the Company, or
Company collaborators, will develop patented federally-approved products
containing Ribi ImmunoChem adjuvants.

It is not certain that Ribi

ImmunoChem will receive federal approval to distribute products
containing its adjuvants

Growth in the highly competitive

blopharmaceutical industry could occur in any direction, and not
necessarily in the direction of (Ribl ImmunoChem*s) molecularlyengineered adjuvants.
Although a thorough competitor analysis has not been undertaken,
the Company perceives itself the world's leader in adjuvant research.
Certainly Edgar Rlbl and his Company colleagues have contributed
immensely to the field, but with new competitors entering the industry
continually, assuming leading competitive advantages is questionable.

2.

Mission and strategies.

Ribi ImmunoChem Research,

its Board of Director's corporate policies.
Company's operating,

Inc. is guided by

The policies direct the

financing, and investing strategies toward
49

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

50

achieving the Board's corporate mlssion--to become a fully integrated
pharmaceutical company focused primarily on development of adjuvants and
human health care adjuvant applications.
Ribl ImmunoChem*s competitive strategy is centered on protecting
its products and technology.

The Board believes that an important

element to Company success is building a strong patent position.
patenting its technology and products,

By

the Company is entitled to large

royalties or licensing fees by any industry researcher who "borrows”
Ribi ImmunoChem discoveries.

The more patents Issued, the better

chances that applications developed by Ribi ImmunoChem will be used by
other industry researchers.
Long-term Company success centers on marketing human health care
products.

Currently,

important malignant and infectious disease

research is examining applications of Ribi ImmunoChem products and
Ingredients.

If any of the research results are approved for

distribution, Ribi ImmunoChem should prosper.

Accordingly, Company

management has devised strategies to enhance chances of approval through
expanded clinical trials and product development efforts.
Expanded clinical trials and product development are expensive.
fund Company operations,

To

Ribi ImmunoChem executives have implemented

financial strategies designed to generate capital to fund operations
until a Company human health care product is approved for commercial
distribution.

Most of the capital has been raised by issuing common

stock to the public,

investing the proceeds in short-term interest

bearing securities, and then selling the securities as needed to provide
operating funds

Additional capital has been raised by negotiating
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contract research awards and improving product sales of RIBIGEN®.
Rlbl ImmunoChem Research,

Inc.

is faced with two problems.

First,

research and development of products worthy of federal approval takes
years and is expensive.

Second, access to particular markets requires

considerable capital to market and distribute products.

In response to

the problems, Ribi ImmunoChem's Board of Directors has devised three
marketing/ distribution strategies to offset the Company's deficiencies.
First,

in the event that the Company is approved to market a

product that is prescribed by doctors for patients, Rlbi ImmunoChem will
market and distribute the product directly to the physicians.

This

strategy will minimize marketing expense and maximize potential profits.
Cancer treatment applications using D E T O X * or OVAMID* to serve multimillion dollar markets would follow this marketing/distribution
strategy.
Second, products approved for distribution which include Company
adjuvants in combination with a partner’s products will become the
partner's marketing/distribution responsibility.

Commercial rights,

royalties, and/or licensing fees will compensate Rlbl ImmunoChem.

This

strategy is designed to address the huge market served by vaccines.
Melanoma treatment developed by Dr. Malcolm Mitchell (University of
Southern California) using D E T O X * would follow this strategy, as would
other research companies testing Ribi adjuvants In Infectious disease
vaccines.
Finally, when a major health care company dominates a market
segment, and if Ribi ImmunoChem Research,

Inc. adjuvants enhance the

major company's products. Ribi ImmunoChem will license its products in
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return for licensing fees and royalties.

Currently Baxter Healthcare

Corporation is researching methods of preventing certain forms of
infectious disease using MPL^, one of Ribl ImmunoChem s proprietary
immunostimulants.
Research,

If Baxter

research is successful, Rlbl ImmunoChem

Inc. would receive

licensing fees and royalties based on

worldwide distribution of products which could serve multi-million,
possibly billion dollar markets.

B.

What is Happening in the

Environment?

1.

Industry analysis.

ImmunoChem Research,

Ribi

complex emerging industry.

Inc. operates in a

Because contemporary techniques for treating

or preventing malignant and infectious diseases are unsafe or
Ineffective, considerable research effort is emerging to counter the
problems.
Industry competitors of varying size and research applications are
entered the new generation blopharmaceutical industry.
Kidder and Peabody estimates,

According to

"by 1990 approximately a dozen known

biotechnology competitors will enter the industry with marketable
products."64

Although specific applications developed by any one of the

competitors could monopolize certain therapy methods (markets),

it is

unlikely any of the competitors can develop products to serve all of the
new human cancer and infectious disease health care needs.

As a result,

the industry is fragmented— none of the competitors can command future
industry leadership.

64 Kidder, Peabody 4 Company, Inc, "Biotechnology Products,
Competitors, and Market Share Assumptions." Asset Valuation Model.
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At present, competition within the emerging blopharmaceutical
industry Is driven by two forces: threats of new entrants, and threats
of substitute technology/products.

As the

develop newly approved products for market,

Industry's competitors
consumers will be

to choose products/treatments for their ailments.
competitor rivalry will likely Intensify.

more free

Accordingly,

More effective products at

affordable prices will become more important considerations to influence
consumer purchasing decisions
In addition, as the industry grows and offers consumers a broader
range of product/treatment selection, customer preference will become a
more significant force.

Responding to customer choices, the industry's

competitors will likely offer Improved service as well.
Current Industry competitors attempt to reduce the immediate
substitute and entrant threats by obstructing or slowing competitor
progress.

A common strategy pursued by the

discoveries.

Additionally,

the competitors

competitors is to

patent all

attempt to create

collaborations between institutions, government agencies, or even other
biotech companies.

The collaborations are hoped to effect new advances

in research and product development— new advances that will benefit the
collaborators.

2.

Competitor analysis.

Because Ribi ImmunoChem Research,

Inc. is

competing in an emerging (future) industry where growth could occur in
many directions, competitor analysis is sketchy.
analysis is not exact,

Even though the

it serves a valuable tool in predicting a

competitor's response to industry change and rivalry.
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Basically,

two Interrelated future goals drive the Industry's

competitors— tremendous profit and market leadership.

Competitors are

racing to improve or develop new technology and products for combatting
infectious and malignant disease.

According to Kidder and Peabody

estimates (table 5), by the time federal approval is granted Ribi
ImmunoChem's D E T O X * (1988), 84% of the Company's biotechnology
competitors will emerge with competing cancer products or technology.
Some may be intended to compete directly with DETO X * in specific
applications,

some may not.

Ribi ImmunoChem officials downplay the

substitute threats (of interferon,

interleukin, monoclonal antibodies,

etc.) as less safe and effective than Ribi ImmunoChem Research,

Inc.

products.
The competitor that first develops improved technology or products
should enjoy tremendous profit and little immediate rivalry.

However,

threats of emerging substitute products or technology pose restrictions
on how long the leader can hold its position.
As an example. Chiron (biotech competitor) announced in 1987 that
the company had received federal approval to market a hepatitis B
vaccine.

The vaccine earned Chiron $70 million in 1987.

Shortly after

Chiron's announcement. Smith, Kline and French also announced approval
to market (in Europe) a substitute vaccine for hepatitis B treatment.
According to recent annual reports, Ribi ImmunoChem Research,

Inc. has

also identified hepatitis B as a possible market for Company products.
The continual threat of substitute products which could Improve
conventional hepatitis B therapy, does not assure Chiron will enjoy the
profit and market leader position forever, nor does it assure Ribl
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ImmunoChem would hold the position long (if Rlbl Introduced an improved
product).
Although each competitor will differ in how it moves products from
the laboratory to the consumer, many similarities will also exist.
First, each competitor will need to secure adequate capital to finance
research and development operations until its products are approved for
commercial distribution.

Second, each competitor will seek product or

technology protection through aggressive patenting

Finally, each

competitor will seek (or internally develop) access to product
distribution channels.
The industry is driven by the hope that current malignant and
infectious disease technology can be improved.

Each competitor draws

favorable conclusions about how effective and safe its product is in
comparison to the competition.

The conclusions often lead to

unsupported claims of industry leadership.

However, from a competitive

analysis perspective, until the products gain federal approval for
customer distribution,

assuming leadership positioning is premature.

Competitive capabilities vary from company to company, and are
subject to change.

Financial strength, innovation, cost positioning,

research/administrative ability, government support, historical market
prominence, and timing all contribute to competitors' strengths and
weaknesses.

Some competitors have distinct advantages at present which

may not continue into the future industry.

To the contrary, some

competitors may have distinct disadvantages at the moment which may
change in the future industry.

As an example, although a small biotech

company may lack capital strength to finance operations long enough to
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bring a product to market,

possible future acquisitions, partnerships,

or mergers can (with the signing of an agreement) provide sufficient
capital backing to strengthen the company's competitiveness.
The greatest competitive advantage in the blopharmaceutical
industry is getting products to market first.
Peabody estimates

According to Kidder and

(Table 5), Amgen, Biogen, and Genentech hold a

competitive advantage by being the first to introduce alpha-interferon
treatment.

Numerous other cancer treatments have been estimated to

reach market before Ribi ImmunoChem Research,

Inc. products.

Kidder and

Peabody estimate 84% of the competitors should introduce a cancer
product before Ribi ImmunoChem.

Many of the products may not compete in

the same Company-sought markets however.
A second competitive advantage in the blopharmaceutical industry is
capturing market share leadership.
estimates, Ribi ImmunoChem Research,

According to Kidder and Peabody's
Inc. will enjoy a monopoly over

markets that seek products containing detoxified endotoxin adjuvants.
Only one other biotech firm can come close to monopolizing specific
cancer markets— estimates predict Immunex will capture 90% of
interleukin-1 markets.
Competitors respond to threats of substitution and rivalry
differently.

Offensively,

competitors are expected to mount campaigns

to Improve chances that they will be the first to introduce new
technology or products.

Accordingly, enhanced clinical research and

product development, and collaborations with private, public, and
government research operations will continue.

Also, forward integration

into marketing and distribution, scale economy production, and seeking
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new applications for previously developed proprietary technology is
expected.

Defensively, all competitors are expected to continue

aggressive product and technology patenting.

3.

Societal analysis.

Changing societal and governmental pressures

will lead to new opportunities and new threats.

With increasing risk of

life-threatening infections (eg: AIDS) and diseases, society is likely
to lobby government for enhanced support of industry research and
product development.

Targeted for developing more effective and safer

substitute technology or products,

the support could include expanded

subsidies and contract research awards.

Easing of federal regulation

may also be sought to rush potentially effective cures to patients
quicker.
Society is also in need of cheaper infectious and malignant disease
treatment.

Societal pressure to lower treatment costs could lead to

Improved liability protection of industry competitors.
On the other side of the coin,

industry competitors are faced with

potential looming threats of product recall.

If following federal

approval, a product is later found unsafe or ineffective» the government
could recall the product.

4. Strength#

Ribi ImmunoChem is technologically well-focused, and

works aggressively toward a concise long-range mission.

The Company

employs the talent of its experienced research and administrative team
to develop a unique approach (molecularly-engineered adjuvants) to
treating select malignant and infectious diseases.
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The disease markets pursued by Ribi ImmunoChem are substantial, and
currently in need of new or improved technology/products.

Two products

are currently undergoing federal human clinical trials, with the first
product

(DETOX^) expected to reach market by 1990 (according to Company

estimates).
Presently, Ribi ImmunoChem enjoys a strong patent position, and
has negotiated research agreements with private and public research
operations to improve chances that a product will be developed which
uses Ribl ImmunoChem adjuvants.

Of major significance, Ribi ImmunoChem

is availing adjuvants to the University of Southern California, the U S
Army Medical Command, and Baxter Healthcare Corporation.

Each of the

partners is capable of providing tremendous research support for long
periods of time.
Although Edgar Ribi's unfortunate death could have limited research
innovation and direction,

it did not.

Ribi ImmunoChem's research staff

is led by scientists who collaborated with or worked under Dr, Ribi's
direction during his pursuit of refining adjuvant technology.

Serving

as a mentor. Dr. Ribi built a team of competent Company scientists
experienced in developing molecularly-engineered adjuvants.
Ribl ImmunoChem Research,
well.

In particular,

Inc. is managed by competent leaders as

under Nils Ribi's presidency, the Company expanded

operations and grew rapidly through public stock offerings, and
profitable Investments.

Understanding his personal limitations however.

Nils Ribi requested the Board of Directors to accept his resignation and
to begin looking for a new president.
the summer of 1987.

Dr. Robert Ivy was recruited in

He brought the Company over thirty years of
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experience at moving pharmaceutical products to market.
Rlbi ImmunoChem Research,

Inc. Is directed by carefully designed

financial and marketing/distribution strategies.

Aimed at efficiently

moving products from clinical testing to customers in the shortest time
possible. Company management has sought methods of financing expanded
clinical research and product development operations.

Proceeds from the

sale of common stock and cash raised from selling short-term securities
has provided most of the capital needed.

Investment interest income and

product sales have also contributed to the capital needed to fund
operations.

Debt has been avoided.

The Company has devised marketing/distribution strategies that
offset customer access drawbacks.

The strategies assure that every

product that reaches federal approval will be moved to the customer in
the shortest time possible, and with the least expense to the Company.
The Company is diversified into research and animal health care
products.

Although Ribl ImmunoChem is not aggressively pursuing animal

health care markets (because the markets are extremely competitive),

the

Company does market a federally approved animal cancer product
(RIBIGEN®).

Future Ribi ImmunoChem strategy provides flexibility in

developing products for animal health care if Company research for human
health care products discovers an application which fits animal health
needs.
Finally, Ribi ImmunoChem Research.
Montana,

Inc. is located in Hamilton,

Besides providing a less expensive operating environment.

Hamilton is near other biotechnology research centers; the University of
Montana, and the Rocky Mountain Laboratory.
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5.

Weaknesses.

Similar to most companies, Ribi ImmunoChem Research.

Inc. suffers weaknesses.

Although the weaknesses are few, any of them

could place the Company at a serious disadvantage.
First,

the Company is adequately capitalized at present, however

the Firm could run out of cash by 1991.

The assessment is depicted in

Table 4 and is based on the following projections:
— > Rlbi ImmunoChem will triple its labor force over the next five
years to 150 employees as Nils Ribi and Bob Ivy have
announced,
— > Product sales will not improve (assuming sales will not improve
significantly until a new product is approved for commercial
distribution),
— > stock issuances will yield the same proceeds as 1987,
--> and the Company will continue the recent trend of
liquidating investment securities to fund operations through
1991 (the point when the pool of securities would run out).

Changes in any one of the assumptions could alter the Company's
solvency position*

However, the changes would need to be dramatic to

markedly improve the Company's solvency.
Second,

the Company's stock prices have fallen drastically.

The

situation places the company in a prime acquisition position for two
reasons: Rlbi ImmunoChem does not control the majority of stock issued,
and the Company appears to be moving closer to federal approval of

Theresa Johnson, "Ribi to Help Fund Graduate Research at UM,"
Missoulian, 20 March 1988, pp.1-2.
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products serving huge markets.
Finally,

the Company has not completed an in-depth competitor

analysis to determine the following three concerns: which companies pose
threats of Introducing competing products; how far the companies are
along in clinical testing; and how well the companies are capitalized.

C.

What Should the Business be Doing?

ImmunoChem Research.

Inc.

In almost all cases, Ribi

is guided by concise strategies tailored to

Company strengths and opportunities.

However, to reduce competitor

threat, and advance the Company's opportunity to reach the Board's
corporate mission (to become a fully integrated pharmaceutical company,
with primary focus on development and application of adjuvants for human
health care) Ribl ImmunoChem Research.

Inc. is encouraged to consider

the following recommendations:

1.

Conduct a thorough competitor analysis.

Research,

Until Ribi ImmunoChem

Inc. can research which competitors pose the most serious

short and long-term threats, devising an effective competitive strategy
is difficult.

Accordingly,

the Company should dedicate resources to

finding answers to critical questions concerning: what companies pose
threats of introducing competing products; how far along the companies
are in clinical testing; and how well

(and by what means) the companies

are capitalized.

2.

To supplement cash flows, expand research and development of

veterinary adjuvant applications.

Although Ribi ImmunoChem Research,
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Inc.'S human health care products are moving closer to federal approval,
the approval may be delayed longer or possibly never granted.

According

to Nils Ribi. approval for human health products takes at least eight
years.

To counter the trend of draining capital reserves to fund

operations through the long approval process,

the Company should expand

efforts to develop veterinary products that are not subject to similar
intense clinical testing.
Currently, the Company markets a veterinary product (RIBIGEN®)
which involved shorter testing and evaluation periods (than products
intended for human health care).

Two years after entering federal

testing phases, RIBIGEN® was approved for commercial distribution.
Aithough RIBIGEN® markets are not substantial, the product generated
sales of $160,000 in 1985.

3.

Postpone expanding the work force.

In March 1988, Nils Ribi

announced that the Company intended to expand the work force from 50 to
150 staff members over the next five years.

According to projections

included in table 4, the expansion would lead to total depletion of
investment securities and cash flows would not cover operating expenses
in 1991.
Expansion of Rlbi ImmunoChem Research, Inc.'s work force is not
necessary to move the first products through later clinical testing
phases.

Prior to the expansion notice, the Company had successfully

operated with adequate staff to move D E T O X * and OVAMID* through pre
cllnlcal and early clinical trials.

The staff size should be adequate

to complete the phase two and three trials of Rlbl ImmunoChem's two
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human health care products.
If expansion were delayed, and sales and stock proceeds remained
the same,

the Company would only need to liquidate $5 million of its

investment securities to generate adequate cash to cover operating
expenses in 1991.

The move would preserve $5.6 million in security

investments for years following 1991 if further liquidation becomes
necessary.

(Table 6 illustrates the cash flow situation if the work

force is not expanded.)
Table 6
RI8I IfHiNOCHW RESeWH, INC
Pro Form Cash Flow (Revised)
(Thousands)

1985

1986

Cash flows from Operating Jtetivities;
Net Income (Loss)
Oepreciation/Amortfzation
Accouits %ceivab1e
Accrued Interest Receivable
Inventories
Other Current Assets
Accounts %yeb1e
Accrued Expenses
Deferred Income

1987

1988

1989

1990

1991

(479)
146
(33)
(255)
41
(22)
(21)
11

55 (1,086) (1,086) (1,086) (1,086) (1,086)
135
147
300
300
300
300
0
9
0
0
0
(4)
0
0
0
(402)
472
0
17
0
0
0
0
(34)
0
(52)
22
0
0
0
(95)
324
0
0
0
0
0
0
0
62 ,
146
0
6
0
0
0
0
(6)

Net Cash Flows from Operating Activities

(612)

(316)

Cash Flows from Investing Activities:
Capital Expenditures
ftp w ts for Other Assets
Change in Investment Securities

32

(786)

(786)

(786)

(786)

(161)
(102)
(10,694)

(204) (2,175)
(49)
(96)
2,714
425

0
0
200

0
0
800

0
0
800

0
0
700

Net Cash Flows from Investing Activities

(10,957)

2,461

(1,846)

200

800

800

700

Cash Flows from Financing Activities:
Proceeds from Issuance of Stock

11,115

19

7

7

7

7

7

(454)

2,164

(1,807)

(579)

21

21

(79)

727

273

2,437

630

51

72

93

$273

$2,437

$630

$51

$72

$93

$14

Net Increase (Decrease in Cash)
Cash-Beginning of Year
Cash— Bid of Year
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RIBI DffJMOCHEM RESEARCH, INC.
Statement» of Operations
Years ended Dflnwnber 31, 1987, 1986 and 1985
1987

1986

1985

475,773
S a l e s ................................ $
Contract ser v i c e s ................
124,136
License and option f e e s ..........
92,903
Investment inoctne, n e t ..........
866,548
O C h e r .................................. .... 4.807

474,502
25,046
—
1,106,708
4.743

370,605
1,225
12,000
595,956
186

1,564,167

1,610,999

979,972

103,300
18,622
788,049
135.449

254,594
1,075
591,776
146.090

1.806.403

1.458.519

Revenues:

Costs and expenses:
165,397
Purchases and production..........
Contract research and development . . .
83,318
Proprietary roaearch and development . . 1,080,617
Depreciation and amoritization...
146.751
2.650.492
less before extraordinary item . .

(1,086,325)

Extraordinary itan-life insurance proceeds

rr

Ket earning# ( l o s s ) .............. Sfl.086.3251
Earning# (loss) per ccmsnn share:
Los# before extraordinary item . . . .
Extraordinazy i t e m ..................

$
(.13)
.......... =r

(195,404)
250.000
____

(478.5471
(.02)
&JSÜL

Net earning# (loss) per
^xjimon s h a r e .......................................aOL.

Avtttag# number of share# outstanding . .

(478,547)

aittfiiiTa
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—

f,Qfi

7.526.917
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RIBI IMMJMOCKEM RESEARCH, INC.
statenttnts of Operations
Years ended Deoenber 31, 1984, 1983, and 1982
1984
Revenues:
Sales ..........
contract research
Interest . . . .
other . . . . . .

Costs and expenses:
Purchases and pro d u cti on ..........
Research and development..........
Selling, general and administrative
Depreciation and anoritization . . .
Int e r e s t..........................
Net loss

1983

1982

$ 402,975
114,100
396,361

206,231
213,434
249,733

175,993
41,536
107,621

913,463

669,963

325,900

164,012
431,296
502,025
103,051
1,299,79%

129,452
249,362
422,647
92,285
ids
-524,123

85,635
112,826
289,101
83,523
-47,523

$0232,2221

_(224.231\

092.7991

3.077.ani:

2.647.Aia

m

232

618.609

loss per g-iiinmn s h a r e ............
Average number of shares outstanding
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RIBI HMJNOCHQl RESEARCH, INC.
Statemtnts of Operations
Inception, January 9, 1981 to Deoanber 31, 1981

Revenues;
S a l e s ..........................................$
I n t e r e s t ....................................
O t h e r ........................................

Tat^l mevenues

~

" 183.020"

Costs and Expenses:
Salaries ....................................
Professional f e e s ............................
Purchases and productif c o s t s ..............
Payroll t a x e s ................................
S u p p l i e s ....................................
Insurance....................................
T r a v e l ......................................
Tele ph one ....................................
I n t e r e s t ....................................
Depreciation and amortization................
o t h e r ........................................

162,475
27,497
18,645
13,471
9,251
11,659
9,437
4,209
23,126
30,357
33,059

Total costs and exoenses
Net loss

65,539
112,481
5,000

343.186
$ (106,166)

Loss per ccmmon share
s
Average number of A a r e e outstanding

r.221
716,852
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RIBI MtJHOCaEM RESEABŒ, Die.
Balance Sheets
31, 1987 a m 1986

.

Assets
current assets:
1987
«
Cash a m short-term d e p o s i t s........
Investment s e c u r i t i e s ...............
?
630,644
Accounts receivable . . . . ! ! ! ! ! * * * ’
1 0 ,3 4 5 , 1 1 2
Accrued interest receivable . ! !
58,312
I n v e n t o r i e s ....................... ! ! ! ’ * *
264,078
Other current a s s e t s ............
192,673
127■
Totl

a s « t , ................

- ll.sia.n»

Property, plant a m equipment:
Equipnient, furniture a m f i x t u r e s ..........

i is, «««

1986
2,437,767
10,770,519
54,498
736,139
209,424
149.416

14.357, 7C-.

873,573
............. i:%S:
1,011,749
o=r-tructlan In p m g r w . ........... ! ! ! ! ! 1

i-IS.Sg

209,728

Accumulated depreciation....................
Net property, plant a m equipment
....

3,5«*440

1.529.473
5fi£x522
1.529.473

Other assets, n e t ....................................

3 *^

314.341
Total a s s e t s

$

is.sea

Curren t liabilities:
Accounts p a y a b l e
$
353,040
Aociuad expenses ............................
235,633
Deferred i n o o a m ............................ ..................
Ittal current liabilities..........

-i25.007

ShareholdscB* equity:
Ptefarred stock, $.10 par, 1 0 ,0 0 0 , 0 0 0 authorized
shares; none issued a m outstanding . . . .
__
cessai stocdc, $.001 par, 2 0 ,0 0 0 , 0 0 0 authorized
ahar w; 8,622,870 a m 8,620,170 issued a m
oustanding in 1987 a m 1986, respectively . .
8,623
Additional paid-in c a p t i t a l ..........
17,463,621
A m a i l a t s d d e f i c i t ..........................
(2,474,711)
Total Aareholders* e q u i t y ..

29,229
89,424
— 6.354

1 4 .9 9 7 . 5 3 3

CcsBittMnts and ocntingsncies:
Tbtal liabilities a m shareholders' equity
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RIBI IMUNOCHEM RESEARCH, INC.
Balance Sheets
Deoanber 31, 1985 and 1984
1985
current assets:

1984

assets

;
Accrued interest r e c e i v a b l e .......... i ........
I n v e n t o r i e s ............................
.
Other current a s s e t s ...............
.........

* "'75,.,07

.............

22x532

Total current assets.................

14,429,186

Property, plant and equipment
Equipment, furniture, fixtures and vehicles

....

3,517,371
30,304
78,815
216,574
75, 0%

3,918,159

aru

679,093
975,665

............................................

^

................................................

Aocunjlatad daçraelatlen.........................
Met property, plant and e c ^ p n e n t ...........
Other assets, n o t ..................................
Total a s s e t s

awz9

ÎTÎS^m

—

84,922

1,739,578
301.850

1,437,728

269.847
$ KLi5a!a,x

171,794

124,619
32x124

145,585
-15.737

T.<*blHttes and
RmltY
current liabilities:
Acsoounts p a y a b l e.................................
Aocrusd expenses.................................
Total current liabilities...........

151.743

iSix312

ShartfibLdsrs* e q jlty
O a a m stock, $.001 par; 10 ,000,000 authorized shares;
8,614,670 and 6,899,800 issued and outstanding in
8,615
1985 and 1984, respectively...................
Additional paid-in c a p ital.......................
17,437,448
Cosmen stock w a rra n ts .........................................................
—
Axnwilatsd d e f i c i t .............................
f1.442.982%

-(064.435%

Total shareholders' etjiity...........

_5J)56,342

l6.003.o8i

ocBBdtaaRts
Tbtal liabilities and shareholders' e g i i ^ ......... $
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pzBi i m m o o i a t peseaboi, m e .
Balano0 S h M t s
n#nmmh#r 31, 1983 and 1982
III

I

1983

Qirrent aaaetat
Cash and money market deposits, irciudiro
U.S. Treasury bills of $953,084 at
December 31, 1983
. . ___
Accounts receivable...................• • . . . ^ 2,653,204
Inventories........................ ! * ’ * * *
Laboratory supplies and o t h e r ............ !! !
Total current a s s e t s .............

2 .9 is.^n^

Property and equipment, at cost:
Equipment, furniture, fixtures and vehicles . . .

_â2*25fl

Accumulated depreciation.....................
Net prcperty and e q u i p m e n t ..........
Other assets, n e t .................................

aai.i^T^
_

3.254 a?*

443,670
339,268
— a3.?5Q
866,688
— 198.19?0
__756.738

8 0 .05a

Total a s s e t s ...................... $ a^a7 7 .n5a

Accounts p a y a b l e .............................
Accrued eagenses .............................
Deferred r e v e n u e .............................

3,061,974
14,351
150,412
28,102

5*75

..........................................

....................................

1982

16,848
12,015

4.034.749

54,878
12,261

Total current liabilities.........
stockholders* equity (note 4):
CcsBon stock, $.001 par; 10,000,000 (5 ,000,000 in
1982) authorised ahares; 3,109,500 and 2,982,500
and outstanding in 1983 and 1982,
respectively.................................
Additional p a i d ^ c a p i t a l .......................
OoBBon stock % m z z a n t s .........................
Accunulated d e f i c i t ...........................

3,109

4,502,937
237

Total stockholders’ e q u i ^ ........ .
Ooamitisents
Total liabilities and stockholders' equity . .$ g + g z j g g
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RIBI D M J N O Œ E M RESEARCH, INC.
Balance Sheet
December 31, 1981
Aseets
current Assets:
si
cash, including certificates of deposit of $460,000 ........
Accounts receivable.........................................\
Inventories....................................................
laboratory supplies............................................
Other
...................................................
Ibtal current assets

389,323
347*955
-- 62.700
770.869
4,993

Other Assets, at Cost, less Applicable Amortization
Total assets

S 1.984 ,122

r.l^tltties W
Eouitv
Current Liabilities:
Notes payable................................................
Accounts p a y a b l e ............................................
Accrued expanses ....................................

$

Total current liabilities
par; authorized 5,000,000 shares; issued and
outstaniing 872,000 s h a r e s ................................
jy&ütionel paid-in capital..................................
—
warrants...........
Déficit accumulated during develqpsant s t a g e .................

“

“Î S S f î l a b U i t l s s and stockholders*

lo'etl
62753
17'458
26!fl2fi

1 .20*

property and Bqaipnent, at Cost:
Bcjjdpnent, furniture and fixtures and vehicles.................
B u i l d i n g s ....................................................
Land .
..................................... ............. __

Ttotal stockholders*

qqo

etjaity..................
equity

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

453,757
12,957
-19.442
486. is6

872
1,657,260
300
—
1.498.266
L i . M i , 4M
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